focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 250.00
Bid: 240.00
Ask: 260.00
Change: 0.00 (0.00%)
Spread: 20.00 (8.333%)
Open: 250.00
High: 250.00
Low: 250.00
Prev. Close: 250.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Renalytix hails trial results; Kingswood buys JFP

Thu, 01st Dec 2022 21:42

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Renalytix PLC - London-based diagnostics company focused on kidney health - Notes the results of primary care use of KidneyIntelX in early-stage chronic kidney disease. Reports a 10% improvement in the HBA1c levels in high-risk patients in first six months. Says that 57% of high-risk patients had action taken within 3-months, compared to 35% for low-risk patients. "The impacts of KidneyIntelX early risk assessment, at 90 days and 180 days, are very encouraging as we can now state that we have observed early intervention in the highest risk patients can result in positive clinical outcomes, before kidney disease advances to a critical point. This prospective study in a real-world health care system setting demonstrates that risk-informed care in the earliest stages of chronic kidney disease is not just a vision, it's a reality," Chief Medical Officer Michael Donovan comments.

----------

Fox Marble Holdings PLC - marble quarrying - Says it was awarded EUR383,177 in damages plus GBP454,584 in costs by in the London Court of International Arbitration from its proceedings against a customer based in India. Says no issues remain to be awarded. The amounts awarded bear an interest rate of 8% per year, it says.

----------

Panther Metals PLC - Canada-focused mineral exploration company - Receives the findings of the follow-up geochemical soil sampling programme 1 in the Barker area of the Manitou Lakes project in Ontario, Canada. Identifies a 300-meter strike extent of linear anomalous and high-grade gold in soils at the Barker prospect area. "These results from the latest round of soil geochemical sampling at Manitou Lakes have almost doubled the strike extent of anomalous gold to 700m at the exciting Barker area prospect in the east of the project area," Chief Executive Darren Hazelwood says.

----------

Kingswood Holdings Ltd - London-based wealth and investment management - Buys Cheshire-based financial advisory firm JFP Holdings Ltd. It is the holding company of JFP Financial Services Ltd. Pays a total cash consideration of up to GBP12.4 million, payable over a two-year period. "The acquisition of JFP Holdings will expand our geographical footprint into the Northwest region and an affluent South Manchester area. JFP Holdings are a high-quality business that has operated with its affiliate Josolyne & Co, a leading chartered accountancy practice, for many years," CEO David Lawrence comments.

----------

Synergia Energy Ltd - Perth-based developer of natural gas assets in India, Indonesia and the UK, formerly called Oilex Ltd - Says that gas production from its C-77H well at the Cambay was around average of 270,000 cubic feet per day in November. Says oil production from the field averaged 23 barrels of oil per day for the month.

----------

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Appoints Maija Hollmen as chief scientific officer. "Hollmen is the world-leading expert on Clever-1 biology and Clever-1-expressing tumour-associated macrophages," Chief Medical Officer Marie-Louise Fjallskog says. "Her support is essential to bexmarilimab's development. Faron is pleased to have her on board in the chief scientific officer role to bring her knowledge of the target molecule and develop it further."

----------

Kropz PLC - African phosphate developer - Says that it agreed to a ZAR121.5 million, or USD7.1 million, bridge loan facility to meet its immediate cash requirements at Elandsfontein. Reports that ZAR242.5 million remains available for drawdown over the term of the ZAR550 million equity facility.

----------

Riverstone Credit Opportunities Income PLC - energy infrastructure and energy-transition credit investor - Realised its investment in Hoover CS with a USD1.6 million gross profit. Also reports an upsized investment in a new sustainability-linked first-lien term loan for Hoover. "Hoover CS has a demonstrated track record of helping its customers across multiple end markets improve environmental performance and the circularity of their supply chains, and we are pleased to partner with them on their next phase of growth. This investment is in-line with our stated yield target and focus on sustainability-linked loans. It also means that RCOI is now almost fully invested," Managing Director Danny Flannery comments.

----------

US Solar Fund PLC - owns and operates solar power assets in North America - Reports changes to key personnel at its investment manager New Energy Solar Manager Pty Ltd. Explains that these changes come amid strategic reviews. Says Liam Thomas will continue to lead the strategic review. Says that Adam Haughton will be leaving NESM in December to pursue an alternative career opportunity. "The board remains fully committed to the strategic review process and is entirely focused on delivering a successful outcome that maximises value for all our shareholders as soon as practically possible. The board would like to wish both Liam and Adam well in their new endeavours and thank them for their commitment to USF since its IPO," Chair Gill Nott says.

----------

Gensource Potash Corp - fertilizer development company based in Saskatchewan, Canada - Plans to raise gross proceeds of CAD6.0 million, or GBP3.6 million, in a non-brokered private placement. The offering will consist of up to 20.0 million units of the company at a price of CAD0.15 per unit. Further, it plans to offer up to 15.0 million common shares at a price of CAD0.20 per flow through share. Intends to use the net proceeds from the sale of the units to advance the Tugaske project.

----------

Atome Energy PLC - Leeds, England-based producer and marketer of green hydrogen and ammonia - Says that it achieved "significant" progress at the Villeta project in Paraguay. Says that its green hydrogen and ammonia Villeta project expanded to a world-scale 120 megawatt capacity capable of producing up to 100,000 metric tonnes of ammonia per year. "We are grateful for the confidence that ANDE [the Paraguayan National Power Company] is showing in Atome by increasing our power supply to 120MW, enabling Paraguay to become the leader on the continent in the fast-growing green hydrogen economy. In parallel, we are announcing that, after a competitive tender process including some of the leading engineers in the field, we have appointed as [front-end engineering design] contractor, a very strong consortium of engineering and industrial companies with a track record of delivering ground-breaking energy projects across Latin America and the world, combined with unparalleled expertise in the ammonia sector," CEO Olivier Mussat comments.

----------

By Abby Amoakuh; abbyamoakuh@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
9 Mar 2020 10:26

Faron gets FDA tick from proposed design of next 'Traumakine' study

(Sharecast News) - Faron Pharmaceuticals announced on Monday that the US Food and Drug Administration (FDA) has accepted its proposed protocol design for the next 'Traumakine' study in acute respiratory distress syndrome (ARDS) patients, following its protocol submission in February.

Read more
5 Mar 2020 14:28

Faron Pharmaceuticals "Encouraged" After Latest Matins Trial Findings

Faron Pharmaceuticals "Encouraged" After Latest Matins Trial Findings

Read more
2 Mar 2020 12:04

Faron Pharmaceuticals Buys Rights For AOC3 Antagonist Platform

Faron Pharmaceuticals Buys Rights For AOC3 Antagonist Platform

Read more
2 Mar 2020 10:08

Faron Pharmaceuticals acquires rights to AOC3 inhibitors

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals has acquired rights for the potential new use of AOC3 inhibitors covered by a recently filed patent application.

Read more
6 Feb 2020 14:17

Faron Pharmaceuticals Alters Traumakine Study After US FDA Feedback

Faron Pharmaceuticals Alters Traumakine Study After US FDA Feedback

Read more
27 Jan 2020 11:22

Faron Pharma To Test Clevegen In Patients With Ovarian Cancer

Faron Pharma To Test Clevegen In Patients With Ovarian Cancer

Read more
13 Jan 2020 11:54

Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug

Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug

Read more
30 Dec 2019 15:39

Faron Pharma requests arbitration over Traumakine manufacturing deal

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Monday that, further to the update on 'Traumakine' drug substance manufacturing on 2 October, it has carried out a detailed investigation into the circumstances around manufacturing arrangements.

Read more
30 Dec 2019 10:56

Faron Pharma Files For Arbitration Amid Traumakine Deal Termination

Faron Pharma Files For Arbitration Amid Traumakine Deal Termination

Read more
11 Dec 2019 13:42

Faron Pharmaceuticals upbeat on new data from 'MATINS' study

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced new data from 'MATINS'-trial patients on Wednesday, to be presented at the ESMO Immuno-Oncology Congress 2019 in Geneva.

Read more
11 Dec 2019 10:45

Faron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance

Faron Pharmaceuticals Pleased With Clevegen Clinical Trial Performance

Read more
29 Nov 2019 10:23

Faron Pharmaceuticals Inks Share Liquidity Pact With Lago Kapital

Faron Pharmaceuticals Inks Share Liquidity Pact With Lago Kapital

Read more
28 Nov 2019 11:56

Faron Pharmaceuticals Says US Regulator Approves Clevegen Drug Status

Faron Pharmaceuticals Says US Regulator Approves Clevegen Drug Status

Read more
21 Nov 2019 12:56

Faron Pharmaceuticals Applies For Nasdaq First North Growth Listing

Faron Pharmaceuticals Applies For Nasdaq First North Growth Listing

Read more
8 Nov 2019 10:30

UK WINNERS & LOSERS SUMMARY: Games Workshop And Beazley Top FTSE 250

UK WINNERS & LOSERS SUMMARY: Games Workshop And Beazley Top FTSE 250

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.